Today, a Director at Boston Scientific Corp (NYSE: BSX), John Sununu, sold shares of BSX for $2,510.
Following John Sununu’s last BSX Sell transaction on July 02, 2018, the stock climbed by 2.1%.
See today’s analyst top recommended stocks >>
Based on Boston Scientific Corp’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $2.49 billion and quarterly net profit of $555 million. In comparison, last year the company earned revenue of $2.26 billion and had a net profit of $146 million. BSX’s market cap is $48.19B and the company has a P/E ratio of 96.92. Currently, Boston Scientific Corp has an average volume of 85.
Based on 16 analyst ratings, the analyst consensus is Strong Buy with an average price target of $37.88, reflecting a -7.9% downside. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy BSX with a $40 price target. Three different firms, including Barclays and Goldman Sachs, currently also have a Sell rating on the stock.
The insider sentiment on Boston Scientific Corp has been negative according to 130 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
John Sununu’s trades have generated a -13.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.
